IGI Logo

Cipla Limited announced that the company has received final approval for its Abbreviated New Drug Application (ANDA) for Arformoterol Tartrate Inhalation Solution from the United States Food and Drug Administration (US FDA). Cipla’s Arformoterol Tartrate Inhalation Solution is AN-rated generic therapeutic equivalent version of Sunovion Pharmaceuticals Inc. 's Brovana.

Brovana® is a long-acting beta-2 adrenergic agonist indicated for administration in the maintenance treatment of bronchoconstriction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema.

We believe that this is an important product approval for the Cipla limited and it will increase its exposure to USA sales from FY2022 itself as the product is ready to be shipped immediately. In the last 12 months, sales of Brovana are around ₹438M as per the IQVIA data and Cipla will launch the generic version of it immediately, so we expect Cipla to have a good opportunity to take market share for Brovana. We have a positive outlook for Cipla Limited.

Above views are of the author and not of the website kindly read disclaimer